Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$7.54 +4.3%	$6.85	$4.09 ▼ $15.92	$161.18M	0.84	280,936 shs	213,585 shs
EPRX Eupraxia Pharmaceuticals	$5.29 -2.2%	$4.49	$2.20 ▼ $6.20	$190.13M	1.55	13,531 shs	4,195 shs
OCUP Ocuphire Pharma		$1.26	$1.07 ▼ $3.40	$30.33M	0.2	171,840 shs	676,700 shs
RGLS Regulus Therapeutics	$8.16	$8.07	$0.83 ▼ $8.35	$564.92M	0.35	1.01 million shs	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	+4.29%	+14.94%	+4.29%	+47.84%	-52.34%
EPRX Eupraxia Pharmaceuticals	-2.22%	-2.74%	+24.76%	+59.82%	+103.46%
OCUP Ocuphire Pharma	0.00%	0.00%	0.00%	0.00%	-42.93%
RGLS Regulus Therapeutics	0.00%	0.00%	-0.61%	+296.12%	+380.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTA Enanta Pharmaceuticals	3.4937 of 5 stars	3.4	1.0	0.0	4.7	0.6	2.5	0.0
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	1.7016 of 5 stars	2.1	5.0	0.0	0.0	0.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	138.73% Upside
EPRX Eupraxia Pharmaceuticals	3.20	Buy	$11.00	107.94% Upside
OCUP Ocuphire Pharma	3.00	Buy	$14.00	∞ Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside

Current Analyst Ratings Breakdown

Latest OCUP, ENTA, EPRX, and RGLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTA Enanta Pharmaceuticals	$67.64M	2.38	N/A	N/A	$6.08 per share	1.24
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	$16.45M	0.00	N/A	N/A	$2.20 per share	0.00
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
OCUP Ocuphire Pharma	-$9.99M	-$0.49	N/A	N/A	N/A	-85.75%	-30.19%	-27.55%	N/A
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)

Latest OCUP, ENTA, EPRX, and RGLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RGLS Regulus Therapeutics	-$0.23	N/A	N/A	N/A	N/A	N/A
8/6/2025	N/A	EPRX Eupraxia Pharmaceuticals	-$0.21	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.10	N/A	N/A	N/A	$16.21 million	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
OCUP Ocuphire Pharma	N/A	10.68	10.68
RGLS Regulus Therapeutics	N/A	16.31	16.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTA Enanta Pharmaceuticals	94.99%
EPRX Eupraxia Pharmaceuticals	N/A
OCUP Ocuphire Pharma	14.97%
RGLS Regulus Therapeutics	92.38%

Insider Ownership

Company	Insider Ownership
ENTA Enanta Pharmaceuticals	13.89%
EPRX Eupraxia Pharmaceuticals	N/A
OCUP Ocuphire Pharma	8.70%
RGLS Regulus Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
OCUP Ocuphire Pharma	14	25.92 million	24.47 million	Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable

OCUP, ENTA, EPRX, and RGLS Headlines

Recent News About These Companies

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $8.50 Average PT from Brokerages

July 17 at 2:03 AM | americanbankingnews.com

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

June 28, 2025 | finance.yahoo.com

Regulus Therapeutics (NASDAQ:RGLS) Upgraded at Wall Street Zen

June 27, 2025 | marketbeat.com

Novartis concludes acquisition of Regulus Therapeutics

June 26, 2025 | medicaldialogues.inM

Novartis concludes Regulus Therapeutics acquisition

June 26, 2025 | pharmaceutical-technology.comP

Press Release: Novartis completes acquisition of Regulus Therapeutics

June 25, 2025 | finanzen.atF

Novartis completes acquisition of Regulus Therapeutics

June 25, 2025 | globenewswire.com

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

June 24, 2025 | pharmabiz.comP

Regulus Therapeutics Inc.

June 21, 2025 | barrons.com

Regulus Therapeutics (NASDAQ:RGLS) Sees Large Volume Increase - What's Next?

June 20, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of "Hold" from Analysts

June 19, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 Shares

June 5, 2025 | insidertrades.com

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)

June 4, 2025 | gurufocus.com

Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout

June 4, 2025 | seekingalpha.com

Novartis commences tender offer to acquire Regulus Therapeutics

May 29, 2025 | pharmabiz.comP

Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows

May 29, 2025 | fiercepharma.comF

Novartis arm commences tender offer to buy Regulus Therapeutics

May 28, 2025 | medicaldialogues.inM

Latham and Covington Advise on Novartis’s Acquisition of Regulus

May 16, 2025 | lawstreetmedia.comL

Regulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 9, 2025 | finanznachrichten.de

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 8, 2025 | prnewswire.com

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

May 4, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
3 Catalysts Driving Plug Power’s Turnaround Case
By Jeffrey Neal Johnson | July 18, 2025
View 3 Catalysts Driving Plug Power’s Turnaround Case
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
Snag These 3 Bargain Tech Stocks Before They Pop
By Gabriel Osorio-Mazilli | June 27, 2025
View Snag These 3 Bargain Tech Stocks Before They Pop
CAVA Group: Why the Growth Story Is Just Getting Started
By Jeffrey Neal Johnson | July 7, 2025
View CAVA Group: Why the Growth Story Is Just Getting Started

OCUP, ENTA, EPRX, and RGLS Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

$7.54 +0.31 (+4.29%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.40 -0.14 (-1.84%)

As of 07/18/2025 04:31 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.29 -0.12 (-2.22%)

Closing price 07/18/2025 03:50 PM Eastern

Extended Trading

$5.34 +0.05 (+0.95%)

As of 07/18/2025 07:48 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Ocuphire Pharma NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time